Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy | Zendy

Naval Daver | Zendy; Jacqueline S. Garcia | Zendy; Brian A. Jonas | Zendy; Kevin R. Kelly | Zendy; Sarit Assouline | Zendy; Joseph Brandwein | Zendy; Pierre Fenaux | Zendy; Rebecca L. Olin | Zendy; Giovanni Martinelli | Zendy; Stefania Paolini | Zendy; Arnaud Pigneux | Zendy; Daniel A. Pollyea | Zendy; Bayard L. Powell | Zendy; Gail J. Roboz | Zendy; Agostino Tafuri | Zendy; Norbert Vey | Zendy; Giuseppe Visani | Zendy; Karen Yee | Zendy; Monique Dail | Zendy; Cherie Green | Zendy; Whitney P. Kirschbrown | Zendy; WanJen Hong | Zendy; Marion Ott | Zendy; Maika Onishi | Zendy; Jue Wang | Zendy; Marina Konopleva | Zendy; Michael Andreeff | Zendy

Open Access

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

Author(s) -

Naval Daver,

Jacqueline S. Garcia,

Brian A. Jonas,

Kevin R. Kelly,

Sarit Assouline,

Joseph Brandwein,

Pierre Fenaux,

Rebecca L. Olin,

Giovanni Martinelli,

Stefania Paolini,

Arnaud Pigneux,

Daniel A. Pollyea,

Bayard L. Powell,

Gail J. Roboz,

Agostino Tafuri,

Norbert Vey,

Giuseppe Visani,

Karen Yee,

Monique Dail,

Cherie Green,

Whitney P. Kirschbrown,

WanJen Hong,

Marion Ott,

Maika Onishi,

Jue Wang,

Marina Konopleva,

Michael Andreeff

Publication year - 2019

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood-2019-123711

Subject(s) - ven , medicine , tolerability , venetoclax , gastroenterology , oncology , mucositis , surgery , adverse effect , chemotherapy , leukemia , chronic lymphocytic leukemia , computer security , computer science

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research